Intravenous/oral ciprofloxacin therapy versus intravenous ceftazidime therapy for selected bacterial infections

The American Journal of Medicine

Volumn 87, Issue 5 SUPPL. 1, 1989, Pages

  Gaut, Paula L ^a   Carron, William C ^a   Ching, Wendell T W ^a   Meyer, Richard D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; CIPROFLOXACIN;

ADULT; AGED; BACTEREMIA; CANDIDA ALBICANS; CLINICAL ARTICLE; CONFERENCE PAPER; FEMALE; FUNGUS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEPHRITIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS; SUPERINFECTION;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BACTERIAL INFECTIONS; CEFTAZIDIME; CIPROFLOXACIN; CLINICAL TRIALS; COMPARATIVE STUDY; DRUG INTERACTIONS; FEMALE; HUMAN; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGE; SUPPORT, NON-U.S. GOV'T;

EID: 0024389648     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9343(89)90051-X     Document Type: Article

References (57)

1. Overview of preclinical studies with ciprofloxacin
2. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro
3. Ciprofloxacin: in vitro, experimental, and clinical evaluation
4. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans
5. An overview of the pharmacology of intravenously administered ciprofloxacin
6. Activities of pefloxacin and ciprofloxacin in experimentally induced Pseudomonas aeruginosa in neutropenic guinea pigs
7. Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia
8. Comparison of ciprofloxacin with aziocillin plus tobramycin in the therapy of experimental Pseudomonas aeruginosa endocarditis
9. Comparative efficacy of ciprofloxacin, ceftazidime and gentamicin given alone or in combination, in a model of experimental septicemia due to Klebsiella pneumoniae in neutropenic mice
10. A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial
11. Efficacy, safety, and potential economic benefits of oral ciprofloxacin in the treatment of infections
12. Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa
13. Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections
14. Efficacy and safety of oral ciprofloxacin in the treatment of serious respiratory infections
15. Use of intravenous ciprofloxacin in difficult-to-treat infections
16. Treatment of serious infections with intravenous ciprofloxacin
17. Evaluacion de la ciprofloxacina en el tratamiento de infecciones bacteriamas graves
18. Use of intravenous ciprofloxacin in respiratory tract infections and biliary sepsis
19. Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections
20. Intravenous ciprofloxacin in the treatment of infection in immunocompromised patients
21. Ciprofloxacin in the treatment of bone infections
22. Analysis of a multicenter clinical study of ciprofloxacin
23. Performance standards for antimicrobial disk susceptibility tests
24. Standards methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
25. Tissue penetration and metabolism of ciprofloxacin
26. Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections
27. Ceftazidime in the treatment of serious Pseudomonas aeruginosa sepsis
28. Ceftazidime in severe infectious: a Swiss multicentre study
29. Open study of ceftazidime in serious infections due to multiply-resistant bacteria
30. Aspects of clinical trials with ceftazidime worldwide
31. Treatment of skin, skin structure, bone, and joint infections with ceftazidime
32. Use of ceftazidime in the treatment of nosocomial lower respiratory infections
33. Evaluation of ceftazidime in the treatment of severe bacterial infection
34. Ceftazidime in the therapy of serious gram-negative bacillary infections
35. Resistance to ciprofloxacin
36. Clinical resistance to long-term oral ciprofloxacin
37. Ciprofloxacin-resistant Pseudomonas
38. Ceftazidime in patients with Pseudomonas infections
39. Reduced sensitivity of B-lactam antibiotics arising during ceftazidime treatment of Pseudomonas aeruginosa infections
40. Ceftazidime therapy of infections caused by Enterobacteriaceae and Pseudomonas aeruginosa
41. Microbial resistance to newer generation B-lactam antibiotics: clinical and laboratory implications
42. Enterococcal superinfection in patients treated with ciprofloxacin
43. Comparative toxicities of the third-generation cephalosporins
44. Ceftazidime: a new broad spectrum cephalosporin
45. Treatment of respiratory tract infections with ciprofloxacin
46. Impact of ciprofloxacin on theophylline clearance and steady-state concentrations in serum
47. Ciprofloxacin increases serum levels of theophylline
48. Increased theophylline concentrations secondary to ciprofloxacin
49. Effects of cimetidine on the pharmacokinetics of pefloxacin in healthy volunteers
50. Drug interactions of ciprofloxacin with other non-antibiotic agents
51. Drug interactions with quinolones
52. Decrease of caffeine elimination in man during coadministration of 4-quinolones
53. The adverse effects of fluoroquinolones
54. Ciprofloxacin and antacids
55. Reduced enteral absorption of ciprofloxacin in the presence of antacids
56. Ciprofloxacin and antacids
57. Sucralfate reduces the gastrointestinal absorption of norfloxacin